Lonza

Lonza Group is a Swiss multinational life-sciences manufacturing and development company headquartered in Basel. Its principal role is to help pharmaceutical and biotechnology companies develop, scale, manufacture, and test medicines and their associated biological or chemical inputs. Rather than primarily selling finished prescription medicines under its own consumer brand, Lonza operates largely as a business-to-business partner, supplying contract development and manufacturing organization services across small molecules, biologics, cell and gene therapies, antibody-drug conjugates, and other specialized modalities. It also has capabilities in delivery technologies, analytical and bioscience services, and selected nutrition and health-related ingredients. The company began in 1897 in Gampel, in the Swiss canton of Valais, and took its name from the nearby Lonza River. Its early activities were closely connected with hydroelectric power and industrial chemistry. Lonza moved its main industrial activity to nearby Visp in 1909, where it continues to operate a major site. During the first half of the twentieth century, the company manufactured calcium carbide, calcium cyanamide, nitrogen products, ammonia, fertilizers, and acetylene-derived chemicals. Its portfolio changed as industrial demand evolved: calcium carbide and related products gave way to nitrogen chemistry, petrochemistry, fine chemicals, and eventually biochemical and pharmaceutical manufacturing. Over time, Lonza shifted from being primarily a commodity and industrial-chemicals producer into a specialized supplier to the pharmaceutical and biotechnology industries. The transition was supported by investments in fine chemical synthesis, biologics manufacturing, analytical systems, and advanced therapies. Partnerships and acquisitions expanded its ability to provide integrated development and production services, including for monoclonal antibodies, biosimilars, cell therapies, gene therapies, and antibody-drug conjugates. Lonza became particularly visible during the COVID-19 pandemic after entering an agreement with Moderna in 2020 to manufacture the active ingredient for Moderna's mRNA-1273 vaccine. Production of mRNA vaccine bulk material began in 2021 at Lonza facilities in Switzerland and the United States. The arrangement made Lonza an important part of the global supply chain for a high-profile vaccine, although the company remained a manufacturing partner rather than the vaccine's owner or developer. The company has maintained a broad international manufacturing network, with more than thirty development and production sites reported across Europe, North America, and Asia. Major locations include Visp in Switzerland, sites in the United States, and operations in countries such as the United Kingdom, Belgium, Spain, France, India, China, Japan, and Singapore. Lonza also expanded through facilities and acquisitions in cell and gene therapy, antibody-drug conjugates, and biologics production. In 2023 it acquired Synaffix, strengthening its antibody-drug conjugate technology offering, and in 2024 completed the acquisition of a Genentech biologics manufacturing site in Vacaville, California, from Roche. In 2024 Lonza announced a strategic move away from capsules and health ingredients, reflecting its intention to concentrate on its core CDMO activities. The company described its focus around integrated biologics, advanced synthesis, and specialized modalities. This repositioning followed weaker post-pandemic demand in parts of the pharmaceutical-supplies market and was intended to simplify the business and prioritize higher-value development and manufacturing services. Lonza remains an active, publicly listed Swiss company whose brand is associated primarily with outsourced pharmaceutical and biotechnology production rather than with a consumer-facing product portfolio.

Lonza originated in 1897 in Gampel in the Swiss canton of Valais. Its first activities were industrial and chemical, supported by the availability of hydroelectric power in the Alpine region. The company developed electrochemical production capabilities and became associated with a range of chemical products and intermediates. This industrial foundation later provided the engineering, process, and manufacturing expertise that supported its move into higher-value specialty chemicals and healthcare-related production. During the twentieth century, Lonza expanded its manufacturing footprint and broadened its chemical portfolio. It became connected with the broader Swiss chemical industry and, for a period, was associated with Alusuisse. The company subsequently developed as an increasingly independent international group, with activities spanning chemicals, pharmaceutical ingredients, and biotechnology. Its transition toward healthcare was gradual rather than based on a single product launch: investment in regulated manufacturing, analytical science, process control, and quality systems created the capabilities required by pharmaceutical customers. In the late twentieth and early twenty-first centuries, Lonza increased its presence in pharmaceutical and biotechnology services. It developed capabilities in active pharmaceutical ingredients, biologics, cell culture, and clinical and commercial supply. This evolution reflected a wider change in the pharmaceutical industry, in which drug companies increasingly outsourced development and manufacturing to specialized partners. Lonza positioned itself as a partner able to support several stages of a product's life cycle, from early process development and clinical material to commercial manufacturing. The company expanded through organic investment and acquisitions. Its purchase of Capsugel in 2017 broadened Lonza into capsules and drug-delivery technologies and made the group more diversified across healthcare manufacturing. Lonza also continued to invest in biologics and advanced therapies, including mammalian cell-culture manufacturing, viral-vector technologies, and cell and gene therapy services. These areas require significant capital, specialized facilities, and extensive regulatory controls, making scale and technical credibility important competitive advantages. The COVID-19 pandemic brought Lonza's manufacturing role into unusually high public visibility. In 2020, Moderna selected Lonza as a manufacturing partner for its mRNA-1273 vaccine. Lonza supported production of vaccine drug substance at multiple sites under an arrangement designed to increase global manufacturing capacity. The collaboration illustrated both the value and the difficulty of rapidly scaling a new biopharmaceutical technology: manufacturing lines, quality systems, raw-material supply, technology transfer, and regulatory requirements had to be coordinated at speed. After the pandemic-related expansion, Lonza continued to focus its portfolio on healthcare and contract manufacturing. It announced the sale of its specialty ingredients business in 2021, reducing exposure to activities that were less central to its CDMO strategy. The company has also periodically reviewed its organizational structure and operating model as demand shifted among small molecules, biologics, and emerging modalities. Its strategy has generally emphasized high barriers to entry, long customer relationships, complex manufacturing processes, and capacity that can serve regulated commercial products. In 2024, Lonza announced an agreement to acquire Roche's biologics manufacturing site in Vacaville, California. The proposed transaction would add a large-scale mammalian manufacturing facility and strengthen Lonza's ability to serve commercial biologics programs in North America. During the same period, Wolfgang Wienand became chief executive officer, succeeding Marc Funk. Under its current direction, Lonza remains focused on being a global development and manufacturing partner for pharmaceutical and biotechnology companies, with principal capabilities across biologics, small molecules, and cell and gene therapies. Its history is therefore best understood as a transformation from a Swiss electrochemical and chemical manufacturer into a specialized global healthcare CDMO.

1. 2024Wolfgang Wienand became chief executive officer

   Wolfgang Wienand succeeded Marc Funk as Lonza's chief executive officer.

   Source
2. 2024Vacaville biologics site acquisition announced

   Lonza agreed to acquire Roche's large-scale biologics manufacturing site in Vacaville, California, subject to transaction completion conditions.

   Source
3. 2021Specialty ingredients business divested

   Lonza announced the sale of its specialty ingredients business to concentrate more closely on healthcare and CDMO activities.

   Source
4. 2020Moderna manufacturing collaboration announced

   Lonza entered a major manufacturing collaboration with Moderna for production of mRNA-1273 COVID-19 vaccine drug substance.

   Source
5. 2017Capsugel acquisition completed

   Lonza completed its acquisition of Capsugel, adding capsule and dosage-form technologies to its healthcare portfolio.

   Source
6. 1999Lonza became an independent publicly traded group

   Lonza was separated from the broader Alusuisse structure and developed as an independently listed Swiss company.

   Source
7. 1897Lonza was established in Valais

   Lonza began operations in Gampel, Switzerland, with industrial and electrochemical activities supported by the region's hydroelectric resources.

   Source

Premium, technically specialized global CDMO serving pharmaceutical and biotechnology companies.

• Biologics CDMOBiologics development and manufacturing

  Lonza develops and manufactures biologic medicines using mammalian and microbial systems. Services can include cell-line and process development, scale-up, analytical characterization, clinical supply, and commercial production. The offering is designed for customers that need access to regulated facilities and specialized manufacturing expertise without building all capacity internally.

• Cell and gene therapy servicesAdvanced therapies

  Lonza provides development and manufacturing support for cell therapies, gene therapies, and viral-vector-based products. The work can cover process development, assay and analytical support, technology transfer, clinical manufacturing, and selected commercial capabilities. These services address products with complex biology, demanding chain-of-custody requirements, and evolving regulatory expectations.

• Small-molecule CDMOPharmaceutical ingredients

  Lonza supports the development and manufacture of small-molecule active pharmaceutical ingredients and related intermediates. Its capabilities include process research, scale-up, clinical material, commercial production, and handling of technically challenging or highly potent compounds. Customers may use the service for both new chemical entities and established products requiring reliable regulated supply.

• Drug-product manufacturingDrug products and fill-finish

  Lonza offers services for converting active ingredients or biologic materials into finished dosage forms. Depending on the program, this can include formulation, sterile processing, fill-finish, packaging, analytical testing, and clinical or commercial supply. The capability links drug-substance manufacturing with later stages of pharmaceutical production.

• Capsules and dosage-form technologiesDrug delivery2017

  Through its former Capsugel activities, Lonza expanded into hard capsules and related dosage-form technologies for pharmaceutical, nutraceutical, and consumer-health applications. This business broadened the company's healthcare manufacturing portfolio, although Lonza later pursued a more focused strategy centered on its core CDMO activities.

• 2020Moderna mRNA-1273 manufacturing collaboration

  United States · Europe · Global

  Lonza worked with Moderna to establish manufacturing capacity for the mRNA-1273 COVID-19 vaccine. The collaboration used Lonza's production network and quality infrastructure to support scale-up of vaccine drug-substance manufacturing during the pandemic.

  Outcome. The collaboration increased available manufacturing capacity for Moderna's vaccine and raised Lonza's profile as a partner for rapid deployment of advanced biologics manufacturing.

  Source

• 2024Acquire Roche's Vacaville biologics manufacturing siteM&A

  Lonza sought additional large-scale mammalian manufacturing capacity in North America to serve commercial biologics customers.

  What changed. Lonza announced an agreement to acquire Roche's Vacaville, California, manufacturing site and related operations, subject to completion conditions.

  Aftermath. The proposed acquisition was intended to expand Lonza's commercial biologics network and deepen its presence in the United States.

  Source
• 2021Divest specialty ingredients activitiesStrategy

  Lonza reviewed its portfolio to concentrate capital and management attention on healthcare and contract development and manufacturing.

  What changed. The company announced the sale of its specialty ingredients business.

  Aftermath. The divestment simplified the portfolio and reinforced Lonza's identity as a focused healthcare CDMO.

  Source
• 2020Scale manufacturing for Moderna's mRNA vaccineStrategy

  The COVID-19 pandemic created urgent demand for manufacturing capacity for Moderna's newly developed mRNA vaccine.

  What changed. Lonza entered a manufacturing collaboration with Moderna and prepared production capacity for vaccine drug substance at Lonza sites.

  Aftermath. The collaboration demonstrated Lonza's ability to support rapid technology transfer and large-scale production of an advanced therapeutic platform.

  Source
• 2017Acquire CapsugelM&A

  Lonza sought to broaden its healthcare portfolio with a business specializing in capsules and dosage-form technologies.

  What changed. Lonza completed the acquisition of Capsugel and integrated its activities into the group.

  Aftermath. The transaction increased Lonza's exposure to pharmaceutical and nutraceutical delivery products, although the group later moved toward a more focused CDMO portfolio.

  Source

• 2024Lonza appointed Wolfgang Wienand as chief executive officer

  Lonza announced Wolfgang Wienand as the successor to Marc Funk, with Wienand taking over as chief executive during 2024.

  Leadership change
  Source
• 2024Lonza announced acquisition of Roche's Vacaville biologics manufacturing site

  Lonza agreed to acquire Roche's large-scale biologics manufacturing site in Vacaville, California, adding mammalian manufacturing capacity and employees to its CDMO network.

  M&A
  Source
• 2021Lonza announced the divestment of its specialty ingredients business

  Lonza agreed to sell its specialty ingredients business as part of a strategic effort to focus the company more tightly on healthcare and CDMO activities.

  M&A
  Source
• 2020Lonza expanded COVID-19 vaccine manufacturing collaboration with Moderna

  Lonza and Moderna announced a manufacturing collaboration to produce drug substance for Moderna's mRNA-1273 COVID-19 vaccine at Lonza sites.

  Product launchOther
  Source
• 2017Lonza completed acquisition of Capsugel

  Lonza acquired Capsugel, expanding its portfolio into hard capsules, dosage-form technologies, and related pharmaceutical and nutraceutical delivery products.

  M&A
  Source

1. Lonza official website
2. Lonza leadership
3. Lonza media releases
4. Lonza article